FDA May Reclassify Peptides for Compounding | Tech News

The FDA is poised to reverse course on peptide restrictions, potentially legalizing custom compounding — a move that could unlock a booming market as GLP-1 drugs normalize at-home injections. Despite internal scientific pushback, industry players are already gearing up, with clinics prescribing unproven peptides and online retailers flooding the market with “research-only” products — all while awaiting the public comment phase that will delay any real-world impact. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/45321e6dfd1e8447